| Literature DB >> 30100185 |
Joo Sang Lee1, Lital Adler2, Hiren Karathia3, Narin Carmel2, Shiran Rabinovich2, Noam Auslander1, Rom Keshet2, Noa Stettner4, Alon Silberman2, Lilach Agemy5, Daniel Helbling6, Raya Eilam7, Qin Sun8, Alexander Brandis9, Sergey Malitsky9, Maxim Itkin9, Hila Weiss2, Sivan Pinto2, Shelly Kalaora10, Ronen Levy10, Eilon Barnea11, Arie Admon11, David Dimmock12, Noam Stern-Ginossar13, Avigdor Scherz7, Sandesh C S Nagamani14, Miguel Unda15, David M Wilson16, Ronit Elhasid17, Arkaitz Carracedo18, Yardena Samuels10, Sridhar Hannenhalli3, Eytan Ruppin19, Ayelet Erez20.
Abstract
The urea cycle (UC) is the main pathway by which mammals dispose of waste nitrogen. We find that specific alterations in the expression of most UC enzymes occur in many tumors, leading to a general metabolic hallmark termed "UC dysregulation" (UCD). UCD elicits nitrogen diversion toward carbamoyl-phosphate synthetase2, aspartate transcarbamylase, and dihydrooratase (CAD) activation and enhances pyrimidine synthesis, resulting in detectable changes in nitrogen metabolites in both patient tumors and their bio-fluids. The accompanying excess of pyrimidine versus purine nucleotides results in a genomic signature consisting of transversion mutations at the DNA, RNA, and protein levels. This mutational bias is associated with increased numbers of hydrophobic tumor antigens and a better response to immune checkpoint inhibitors independent of mutational load. Taken together, our findings demonstrate that UCD is a common feature of tumors that profoundly affects carcinogenesis, mutagenesis, and immunotherapy response.Entities:
Keywords: CAD; cancer metabolism; immunotherapy; mutagenesis; pyrimidines; urea cycle
Mesh:
Substances:
Year: 2018 PMID: 30100185 PMCID: PMC6225773 DOI: 10.1016/j.cell.2018.07.019
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582